|
Denis Loredan, PhDDenis received his BS in Cell & Molecular Biology from Binghamton University in 2014, where a course in immunology first inspired him to pursue further studies on the subject. After graduation, he worked for two years as a research technician at the Institute for Cancer Genetics at Columbia University Medical Center in the lab of Dr. Shan Zha, where he studied the molecular mechanisms of DNA damage and repair in lymphocytes, and how defects in the repair process lead to oncogenic transformation. He also gained invaluable experience as manager of the lab mouse colony and working with in vivo mouse models of disease. In August 2016 Denis started graduate school at New York University, where he developed an interest in host-pathogen interactions and how various states of inflammation are regulated. For his thesis work, Denis is focusing on the immune response to parasitic helminth infections and immunological memory.
Research Interest: Host-Pathogen interactions, Parasite Immunology, T cell biology, Immunological memory, Flow cytometry, Immune regulation, Immunometabolism Awards/Accolades:
Teaching Experience:
Fun Fact: Despite his city roots, Denis is an avid hiker who has explored much of the Hudson Valley and the famed Catskill Mountains north of NYC. Always appreciative of a great view and a new ecosystem, Denis has hiked in places ranging from Switzerland to South Africa to the Smoky Mountains of Tennessee. Hometown: New York City, NY B.S. in Cell & Molecular Biology – Binghamton University, SUNY – 2014 M.S. in Immunology & Inflammation – New York University - 2018 |
Publications |
Roohi J, Crowe J, Loredan D, Anyane-Yeboa K, Mansukhani MM, Omesi L, Levine J, Revah Politi A, Zha S. New diagnosis of atypical ataxia-telangiectasia in a 17-year-old boy with T-cell acute lymphoblastic leukemia and a novel ATM mutation. J Hum Genet. 2017 Apr;62(5):581-584.
Yamamoto K, Wang J, Sprinzen L, Xu J, Haddock CJ, Li C, Lee BJ, Loredan DG, Jiang W, Vindigni A, Wang D, Rabadan R, Zha S. Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. Elife. 2016 Jun 15;5 Pinkney KA, Jiang W, Lee BJ, Loredan DG, Li C, Bhagat G, Zha S. Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas. J Hematol Oncol. 2015 Jul 30;8:94. |